Please ensure Javascript is enabled for purposes of website accessibility

How Does Johnson & Johnson's COVID Vaccine Approval Affect Moderna?

By Keith Speights and Brian Orelli, PhD - Mar 12, 2021 at 6:14AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Not much -- at least for now.

The dynamics in the COVID-19 vaccine market continue to shift. Johnson & Johnson (JNJ -0.57%) recently won Emergency Use Authorization for its vaccine from the U.S. Food and Drug Administration. In this Motley Fool Live video, recorded on March 3, contributors Keith Speights and Brian Orelli answer a viewer's question about how J&J's authorization could impact another leader in the COVID-19 vaccine space, Moderna (MRNA 5.95%).

Keith Speights: How does J&J's approval affect Moderna stock? What's your take on that one?

Brian Orelli: I think I saw Moderna dropped on Monday after the weekend approval. [Laughter] Which seems ridiculous both because I'm not sure that it really affects their ability to sell their vaccine. It's not going to affect their ability to sell the vaccine this year because they've already got supply agreements with the United States.

Johnson and Johnson was going to get approved. If anybody thought otherwise, they were in the very minority camp. It seems weird that it's going down and it's falling more, selling the news issue than an actual reason to justify.

Speights: I would agree. I mean, look, the news might impact the stock but it's not going to impact Moderna's business and that's the more important thing over the long run. At least it probably won't.

I guess there is that possibility that after this year if Johnson & Johnson's price is significantly lower -- they're selling it at cost right now. But after the pandemic is over, they'll want to make a profit from it. Cost could play a factor, the single-dose advantage could play a factor, but also remember the variants.

Brian, you and I have talked about this before, that the mRNA vaccines probably will be better and better positioned to respond rapidly to new variants that might emerge. That could get Moderna a leg up over Johnson & Johnson over the long run, in the COVID vaccine space anyway.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$137.91 (5.95%) $7.74
Johnson & Johnson Stock Quote
Johnson & Johnson
$176.85 (-0.57%) $-1.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.